Introduction {#s1}
============

SOX2 overlapping transcript (SOX2-OT) is a long non-coding RNA located in 3q26.33 locus. Its third intron harbors SOX2 gene which encodes the transcription factor SOX2, an established pluripotency state modulator ([@B2]; [@B5]; [@B6]). Several studies revealed that SOX2-OT levels were consistently positively correlated with SOX2 levels. SOX2-OT plays a role in proliferation of cells and SOX2 regulation ([@B1]; [@B7]; [@B14]; [@B15]).

It has been shown that lncRNA SOX2-OT is overexpressed in a number of human cancers as an oncogene promoting tumorigenesis and cancer progression, including ovarian cancer, breast cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, hepatocellular carcinoma, esophageal squamous cell carcinoma, osteosarcoma, non-small cell lung cancer, and gastric cancer ([@B8]; [@B27]; [@B29]; [@B23]; [@B24]; [@B6]; [@B10]; [@B11]; [@B19]; [@B21]; [@B25]; [@B26]). SOX2-OT is co-upregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma and potentially involved in maintaining the pluripotent state of stem cells ([@B14]). Although these articles established the critical role of lncRNA SOX2-OT expression in some cancers, the prognostic value of SOX2-OT expression in numerous other cancers remained uncharacterized ([@B15]; [@B3]; [@B4]). In addition, inconsistent results were obtained in several studies on the association between SOX2-OT expression and clinical features such as tumor size, clinical stage, and tumor invasion ([@B16]; [@B29]; [@B23]; [@B11]; [@B19]).

The evidence above showed that SOX2-OT is involved in tumor progression. Moreover, an earlier meta-analysis study published in 2018 had revealed that the overexpression of SOX2-OT was significantly correlated with the overall survival (OS), clinical stage, lymph node metastasis, distant metastasis, and tumor differentiation of cancers ([@B17]). However, the sample size of the study was restricted, and the relationship between SOX2-OT and other clinicopathological characteristics was not explored ([@B17]). As described below, we have conducted a more comprehensive trial sequential analysis (TSA) on the applicable literature and searched The Cancer Genome Atlas (TCGA) database to study the prognostic value of SOX2-OT in patients with several types of cancer. We additionally explored the potential target genes of SOX2-OT through gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses, and the potential mechanisms of SOX2-OT in tumor progression are also discussed.

Methods {#s2}
=======

Search Strategy {#s2_1}
---------------

Studies on the prognostic roles of SOX2-OT in cancer patients that were published as of October 1st, 2019 were extracted from the electronic databases PubMed, EMBASE, and Cochrane Library using the terms (1) "SOX2-OT" OR "NCRNA00043" OR "SOX2OT" OR "SOX2 overlapping transcript" OR "SRY-box transcription factor 2 overlapping transcript" AND (2) "tumor OR cancer OR carcinoma OR neoplasm OR metastasis". The search strategies are illustrated in [**Supplementary Table 1**](#ST1){ref-type="supplementary-material"}. The search and selection of articles for the study were conducted as described previously ([@B20]).

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Studies entering this analysis met these requirements: (1) definitive diagnosis or histopathological confirmation for patients with cancer; (2) the expression of SOX2-OT must be measured by quantitative real-time polymerase chain reaction (qRT-PCR); (3) the hazard ratios (HRs) and their 95% confidence intervals (CIs) for survival parameters based on SOX2-OT expression levels were promptly available or could be calculated indirectly; and (4) the representative and accurate studies were selected to avoid unnecessary cohort overlapping. Studies that have satisfied the abovementioned inclusion requirements were further ruled out if they had any of the following features: (1) duplicated articles or data; (2) non-human studies; (3) review articles or letters; (4) articles in non-English languages.

Quality Assessment of Included Studies {#s2_3}
--------------------------------------

The quality of the included studies was assessed using Newcastle-Ottawa Scale (NOS), with scores ≥ 6 considered high quality. A ''star system'' was applied for case-control studies ([**Supplementary Table 2**](#ST2){ref-type="supplementary-material"}).

Data Extraction {#s2_4}
---------------

The following information was extracted from each study: (1) first author; (2) publication year; (3) nationality, sample size, tumor type, and clinicopathological characteristics of involved patient population; (4) the assay method and cut-off value of SOX2-OT expression levels; (5) HRs of SOX2-OT expression for OS and disease-free survival (DFS). If the HRs for OS and DFS were calculated by both univariate and multivariate analyses, the latter were our first choice for these results and were adjusted for confounding factors. If a study did not report HRs, we estimated HRs and their corresponding 95% CIs using the procedure described by [@B12] and [@B22]. The data of Kaplan-Meier curves were regained by Engauge Digitizer software (version 9.8, <http://markummitchell.github.io/engauge-digitizer>). This process was repeated three times to decrease variability. Discrepancies were resolved through discussion and review of extraction until consensus was reached on a final list of factors targeted by each study.

Statistical Analysis {#s2_5}
--------------------

All the HRs and their 95% CIs were integrated to evaluate the association between SOX2-OT expression and prognosis. If the pooled HR \< 1 and their 95% CI did not overlap the invalid line in the forest plot, the elevated expression of SOX2-OT predicted a good OS. The heterogeneity of the pooled results was examined *via* Cochrane's Q test and Higgins' I-squared. If *P* ≥ 0.1 and I^2^ ≤ 25%, we disregarded the influence of heterogeneity and pooled the overall result using a fixed effects model, otherwise employing the random effects model. Potential publication bias was assessed by a funnel plot and Egger's test ([@B18]) conducted using the "metafor" and "meta" packages of R (version 3.2.3). All of the abovementioned methods followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) Checklist.

Results {#s3}
=======

Identification of Eligible Studies {#s3_1}
----------------------------------

Identification of eligible studies is summarized in [**Figure 1**](#f1){ref-type="fig"}. We screened 122 articles for eligibility and identified 13 eligible studies. These eligible articles were published between 2014 and 2018 and included a total of 1172 participants who represented eight cancer types ([**Table 1**](#T1){ref-type="table"}). Most articles choose the mean and median as the cutoff value. Eight studies that used multivariate analysis of OS were included in the meta-analysis ([@B7]; [@B16]; [@B27]; [@B29]; [@B23]; [@B10]; [@B11]; [@B26]), the adjusted variables of the multivariate analysis were presented in [**Table 2**](#T2){ref-type="table"}. The other three studies provided survival curves ([@B28]; [@B19]; [@B25]).

![Flow chart of the identification of eligible studies.](fgene-10-01375-g001){#f1}

###### 

Main characteristics of the 13 included studies.

  Author     Year   Study design                  Country   Case (N)   Type of cancer                     Study period                            Treatment                                                                                                                              Disease stage   Maximum follow up (mo)   Sample type        Assay     Cut-off value   Survival end points   Analysis of OS   Adjusted variables                                                            NOS score
  ---------- ------ ----------------------------- --------- ---------- ---------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------------ ------------------ --------- --------------- --------------------- ---------------- ----------------------------------------------------------------------------- -----------
  Wang       2017   Retrospective single-center   China     138        Osteosarcoma                       2008.01--2016.01                        Received antitumor treatment                                                                                                           I--III          72                       Tissue (-)         qRT-PCR   Median          OS, CP                Multivariate     Enneking stage, tumor size, distant metastasis, histological grade            7
  Zhang      2017   Retrospective single-center   China     50         Pancreatic ductal adenocarcinoma   2006--2012                              Underwent pancreaticoduodenectomy for pancreatic cancer, no chemotherapy or radiation therapy was administered before tumor excision   I--IV           62                       FTT                qRT-PCR   NA              OS                    Survival curve   NA                                                                            7
  Han        2018   Retrospective single-center   China     105        Ovarian cancer                     2013--2015                              Underwent surgeries, not treated with chemotherapy or radiotherapy prior to surgery.                                                   I--IV           NA                       Tissue (-)         qRT-PCR   Median          CP                    NA               NA                                                                            6
  Li ZL      2018   Retrospective single-center   China     58         Cholangiocarcinoma                 2010.03--2012.07                        Never received chemotherapy or radiotherapy before surgical resection                                                                  I--IV           60                       FTT                qRT-PCR   Median          OS, CP                Multivariate     Lymph node invasion, vascular invasion, TNM stage, postoperative recurrence   8
  Hou        2014   Retrospective single-center   China     83         Lung cancer                        2005--2008                              NA                                                                                                                                     I--IV           99                       FTT                qRT-PCR   NA              OS                    Multivariate     Smoking status, TNM stage, lymphatic metastasis                               7
  Shi        2015   Retrospective single-center   China     84         Hepatocellular carcinoma           2006--2008                              Underwent a curative hepatectomy                                                                                                       I--IV           60                       Tissue (-)         qRT-PCR   Median          OS, CP                Multivariate     Histologic grade, TNM stage, vein invasion                                    7
  Iranpour   2016   Retrospective single-center   Iran      38         Breast cancer                      NA                                      NA                                                                                                                                     I--IV           NA                       FTT                qRT-PCR   NA              CP                    NA               NA                                                                            7
  Zhang      2016   Retrospective single-center   China     132        Gastric cancer                     NA                                      NA                                                                                                                                     I--IV           96                       FTT                qRT-PCR   Median          OS, CP                Multivariate     Clinical stage, tumor depth, lymph node metastasis, distant metastasis        8
  Zou        2016   Retrospective single-center   China     155        Gastric cancer                     NA                                      Without any therapeutic before surgery                                                                                                 I--IV           65                       Tissue (-)         qRT-PCR   Median          OS, DFS, CP           Multivariate     T stage, distant metastasis, differentiation                                  8
  Xie        2018   Retrospective single-center   China     100        NSCLC                              2010.01--2012.02                        No chemotherapy or radiotherapy was received before tissue/serum collection                                                            I--III          46                       Tissue and serum   qRT-PCR   Median          OS                    Multivariate     Tumor size, lymph node metastasis, TNM stage                                  7
  Sun        2018   Retrospective single-center   China     86         Hepatocellular carcinoma           2009.11--2014.03                        Underwent surgical resection                                                                                                           I--IV           61                       FTT                qRT-PCR   mean            OS, DFS, CP           Survival curve   NA                                                                            7
  Li ZH      2018   Retrospective multicenter     China     61         Pancreatic ductal adenocarcinoma   2012.01--2016.01 and 2015.07--2015.10   NA                                                                                                                                     I--IV           45                       Serum              qRT-PCR   mean            OS, CP                Multivariate     Liver metastasis                                                              8
  Wei        2018   Retrospective single-center   China     82         Cholangiocarcinoma                 NA                                      NA                                                                                                                                     I--IV           60                       FTT                qRT-PCR   mean            OS, CP                Survival curve   NA                                                                            7

mo., month; NSCLC, non-small cell lung cancer; NA, not available; NOS, Newcastle-Ottawa Scale; OS, overall survival; DFS, disease-free survival; -, not mentioned; FTT, Frozen tumor tissue; q-PCR, quantitative real-time polymerase chain reaction; CP, clinical parameters; TNM, tumor, node, metastasis.

###### 

The adjusted variables in the multivariate analysis of OS in the 8 included studies.

  Author   Year   Clinical stage   Lymph node metastasis   Tumor differentiation   Tumor size   Vascular invasion   Tumor depth   Distant metastasis   Postoperative recurrence   Smoking status
  -------- ------ ---------------- ----------------------- ----------------------- ------------ ------------------- ------------- -------------------- -------------------------- ----------------
  Wang     2017   √                                        √                       √                                              √                                               
  Li ZL    2018   √                √                                                            √                                                      √                          
  Hou      2014   √                √                                                                                                                                              √
  Shi      2015   √                                        √                                    √                                                                                 
  Zhang    2016   √                √                                                                                √             √                                               
  Zou      2016                                            √                                                        √             √                                               
  Xie      2018   √                √                                               √                                                                                              
  Li ZH    2018                                                                                                                   √                                               

OS, overall survival.

Association Between SOX2-OT Expression and Prognosis {#s3_2}
----------------------------------------------------

We carried out a meta-analysis of the association between SOX2-OT expression and OS and DFS. The results revealed that higher SOX2-OT expression predicted an unfavorable OS (n = 11, HR = 2.026, 95% CI: \[1.691--2.428\], *P* \< 0.0001, I^2^ = 0%) ([**Figure 2A**](#f2){ref-type="fig"}) and a poor DFS (n = 2, HR = 2.554, 95% CI: \[1.261--5.174\], *P* = 0.0092, I^2^ = 66.6%, [**Supplementary Figure 1**](#SF1){ref-type="supplementary-material"}, [**Table 3**](#T3){ref-type="table"}). No heterogeneity was identified according to a fixed effect model (I^2^ = 0%) ([**Figure 2A**](#f2){ref-type="fig"}). The outcomes of publication bias analysis are listed in [**Table 3**](#T3){ref-type="table"}.

![Relationship between SOX2 overlapping transcript (SOX2-OT) expression and overall survival (OS) in patients with various cancers. **(A)** Forest plot of SOX2-OT expression and OS. **(B)** trial sequential analysis (TSA) of 11 trials comparing OS of the high vs. low SOX2-OT expression. Heterogeneity adjustment required information size of 1990 participants calculated on basis of proportion of OS of 80%, RRR of 15%, α = 5%, β = 20%, power = 0.80, and I^2^ = 0%. Cumulative Z-curve crosses trial sequential monitoring boundary, showing sufficient evidence for a 15% increase in relative risk with high expression of SOX2-OT. Horizontal green lines illustrate the traditional level of statistical significance (*P* = 0.05).](fgene-10-01375-g002){#f2}

###### 

Meta-analysis of the effects of SOX2-OT overexpression on survival and clinical parameters.

  Outcome                                           No. of trials (patients)   HR or RR(95% CI)             *P* value of Fixed-effect Model   *Z value of Fixed-effect Model*   HR or RR(95% CI)             *P* value of Random-effect Model   *Z* value of Random-effect Model   Heterogeneity I^2^(%), *P* value   *P* value of Egger's test, Begg's test
  ------------------------------------------------- -------------------------- ---------------------------- --------------------------------- --------------------------------- ---------------------------- ---------------------------------- ---------------------------------- ---------------------------------- ----------------------------------------
  OS                                                11 (1029)                  ***2.026 (1.691--2.428)***   ***\<0.0001***                    7.6500                            2.026 (1.691--2.428)         \<0.0001                           7.6500                             0.0%, 0.9698                       0.0135, 0.0158
  DFS                                               2 (241)                    2.332 (1.593--3.413)         \<0.0001                          4.3575                            ***2.554 (1.261--5.174)***   ***0.0092***                       2.6045                             66.6%, 0.0836                      NA, NA
  Tumor stage (**III/IV versus I/II**)              9 (784)                    1.526 (1.325--1.758)         \<0.0001                          5.8585                            ***1.468 (1.106--1.949)***   ***0.0079***                       2.6566                             71.9%, 0.0004                      0.8772, 0.8348
  Lymphatic metastasis (**yes versus no**)          7 (631)                    1.534 (1.311--1.794)         \<0.0001                          5.3453                            ***1.554 (1.211--1.994)***   ***0.0005***                       3.4685                             52.2%, 0.0508                      0.4831, 0.8806
  Distant metastasis (**yes versus no**)            4 (486)                    ***3.054 (1.866--4.999)***   ***\<0.0001***                    4.4415                            2.957 (1.620--5.400)         0.0004                             3.5295                             18.3%, 0.2989                      0.1705, 0.1742
  Tumor size (**large versus small**)               7 (667)                    1.285 (1.118--1.478)         0.0004                            3.5306                            ***1.264 (1.019--1.566)***   ***0.0329***                       2.1336                             56.2%, 0.0330                      0.3387, 0.2931
  Depth of tumor invasion (**T3/4 versus T1/2**)    3 (369)                    ***1.552 (1.274--1.890)***   ***\<0.0001***                    4.3703                            1.557 (1.280--1.894)         \<0.0001                           4.4300                             0.0%, 0.9288                       0.5396, 0.6015
  Differentiation (**poor/moderate versus well**)   9 (834)                    1.131 (0.978--1.309)         0.0977                            1.6560                            1.122 (0.800--1.573)         0.5062                             0.6647                             78.7%, \<0.0001                    0.5987, 0.2971
  Age (elder versus young)                          10 (929)                   0.981 (0.862--1.116)         0.7661                            -0.2975                           0.966 (0.821--1.138)         0.6812                             -0.4108                            31.4%, 0.1575                      0.1080, 0.3970
  Gender (**male versus female**)                   8 (796)                    1.022 (0.921--1.134)         0.6798                            0.4128                            1.013 (0.916--1.122)         0.7959                             0.2587                             0.0%, 0.8005                       0.5557, 0.3223

HR, hazard ratio; RR, relative risk; CI, confidence interval; OS, overall survival; DFS, disease-free survival; NA, not available.

I^2^, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity.

Egger's test: P value of Egger's regression for asymmetry assessment.

Begg's test: P value of Begg and Mazumdar rank correlation test for asymmetry assessment.

Bold italics indicate statistically significant values (P \< 0.05).

We performed subgroup analyses of association between SOX2-OT expression and OS using 11 studies. The results showed the presence of a significant association between SOX2-OT expression and OS when the data were fully integrated from eight studies where OS was assessed with multivariate analysis (HR = 2.052, 95% CI: \[1.661; 2.536\], *P* \< 0.0001, I^2^ = 0%) ([**Table 4**](#T4){ref-type="table"}). Furthermore, a significant relationship was revealed in the subgroup analyses for OS based on sample size (*P* \< 0.0001), tumor type (*P* \< 0.05), sample type (*P* \< 0.05), and cut-off value (*P* \< 0.01).

###### 

Subgroup analysis of the association between SOX2-OT overexpression and OS in patients with different cancers.

  Sub variates                        No. of trials   HR (95% CI) (FEM)             P value (FEM)    HR (95% CI) (REM)       P value (REM)   Heterogeneity I^2^, *P*   Heterogeneity Q   Heterogeneity tau^2^   P between subgroup (REM)
  ----------------------------------- --------------- ----------------------------- ---------------- ----------------------- --------------- ------------------------- ----------------- ---------------------- --------------------------
  Sample size                                                                                                                                                                                                   
   ≥100                               4               ***1.942\[1.486; 2.539\]***   ***\<0.0001***   1.942\[1.486; 2.539\]   \<0.0001        0.00%, 0.5595             2.0625            \<0.0001               0.6764
   ≤100                               7               ***2.099\[1.642; 2.682\]***   ***\<0.0001***   2.099\[1.642; 2.682\]   \<0.0001        0.00%, 0.9777             1.1828            \<0.0001               
  Tumor type                                                                                                                                                                                                    
   Osteosarcoma                       1               ***1.659\[1.042; 2.641\]***   ***0.0328***     1.659\[1.042; 2.641\]   0.0328          NA, 1.0000                \<0.0001          NA                     0.9369
   Pancreatic ductal adenocarcinoma   2               ***1.887\[1.203; 2.959\]***   ***0.0057***     1.887\[1.203; 2.959\]   0.0057          0.00%, 0.9452             0.0047            \<0.0001               
   Cholangiocarcinoma                 2               ***2.150\[1.270; 3.637\]***   ***0.0043***     2.150\[1.270; 3.637\]   0.0043          0.00%, 0.9803             0.0006            \<0.0001               
   Lung cancer                        2               ***2.019\[1.265; 3.222\]***   ***0.0032***     2.019\[1.265; 3.222\]   0.0032          0.00%, 0.4068             0.6882            \<0.0001               
   HCC                                2               ***2.125\[1.451; 3.113\]***   ***0.0001***     2.125\[1.451; 3.113\]   0.0001          0.00%, 0.4559             0.5558            \<0.0001               
   Gastric cancer                     2               ***2.299\[1.525; 3.467\]***   ***0.0001***     2.299\[1.525; 3.467\]   0.0001          0.00%, 0.3456             0.8894            \<0.0001               
  Sample type                                                                                                                                                                                                   
   Tissue                             9               ***2.080\[1.699; 2.546\]***   ***\<0.0001***   2.080\[1.699; 2.546\]   \<0.0001        0.00%, 0.9289             3.0847            \<0.0001               0.8458
   Mix                                1               ***1.793\[1.040; 3.092\]***   ***0.0357***     1.793\[1.040; 3.092\]   0.0357          NA, 1.0000                \<0.0001          NA                     
   Serum                              1               ***1.860\[1.015; 3.408\]***   ***0.0445***     1.860\[1.015; 3.408\]   0.0445          NA, 1.0000                \<0.0001          NA                     
  Cut-off value                                                                                                                                                                                                 
   Median                             6               ***2.040\[1.616; 2.575\]***   ***\<0.0001***   2.040\[1.616; 2.575\]   \<0.0001        0.00%, 0.7362             2.7648            \<0.0001               0.9231
   others                             2               ***2.196\[1.279; 3.771\]***   ***0.0043***     2.196\[1.279; 3.771\]   0.0043          0.00%, 0.5099             0.4343            \<0.0001               
   mean                               3               ***1.935\[1.379; 2.714\]***   ***0.0001***     1.935\[1.379; 2.714\]   0.0001          0.00%, 0.9702             0.0604            \<0.0001               
  Analysis model                                                                                                                                                                                                
   Multivariate                       8               ***2.052\[1.661; 2.536\]***   ***\<0.0001***   2.052\[1.661; 2.536\]   \<0.0001        0.00%, 0.8533             3.3257            \<0.0001               0.8178
   Survival curve                     3               ***1.956\[1.380; 2.773\]***   ***0.0002***     1.956\[1.380; 2.773\]   0.0002          0.00%, 0.9798             0.0408            \<0.0001               

HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC, hepatocellular carcinoma; FEM, fixed-effect model; REM, random-effect model; NA, not available.

I^2^, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity.

Bold italics indicate statistically significant values (P \< 0.05).

Eight studies employed Cox multivariate analysis to survey the prognostic value of lncRNA SOX2-OT expression on the prognosis of cancer patients ([@B7]; [@B16]; [@B27]; [@B29]; [@B23]; [@B10]; [@B11]; [@B26]). An in-depth subgroup analysis is required to clearly define the values of the adjusted variables in multivariate analysis ([**Table 5**](#T5){ref-type="table"}). Subgroup analysis stratified by independent prognostic factors, such as clinical stage (*P* \< 0.0001), lymph node metastasis (*P* \< 0.0001), tumor differentiation (*P* \< 0.0001), tumor size (*P* \< 0.01), vascular invasion (*P* \< 0.001), tumor depth (*P* \< 0.001), distant metastasis (*P* \< 0.0001), postoperative recurrence (*P* \< 0.05), and smoking status (*P* \< 0.05) ([**Table 5**](#T5){ref-type="table"}) demonstrated that a significant relationship existed between lncRNA SOX2-OT expression and OS.

###### 

Subgroup analyses of the OS in the eight included studies based on adjusted variables.

  Sub variates               No. of trials   HR (95% CI)                   P value (FEM)    HR (95% CI)             P value (REM)   Heterogeneity I^2^, *P*   Heterogeneity Q   Heterogeneity tau^2^   P between subgroup
  -------------------------- --------------- ----------------------------- ---------------- ----------------------- --------------- ------------------------- ----------------- ---------------------- --------------------
  Clinical stage                                                                                                                                                                                       
  YES                        6               ***2.007\[1.587; 2.538\]***   ***\<0.0001***   2.007\[1.587; 2.538\]   \<0.0001        0.00%, 0.8483             2.0058            \<0.0001               0.8855
  NO                         2               ***2.260\[1.388; 3.681\]***   ***0.0010***     2.283\[1.350; 3.859\]   0.0021          11.85%, 0.2868            1.1344            0.0183                 
  Lymph node metastasis                                                                                                                                                                                
  YES                        4               ***2.060\[1.532; 2.771\]***   ***\<0.0001***   2.060\[1.532; 2.771\]   \<0.0001        0.00%, 0.8694             0.7161            \<0.0001               0.9731
  NO                         4               ***2.044\[1.511; 2.765\]***   ***\<0.0001***   2.044\[1.511; 2.765\]   \<0.0001        0.00%, 0.4561             2.6082            \<0.0001               
  Tumor differentiation                                                                                                                                                                                
  YES                        3               ***2.109\[1.488; 2.990\]***   ***\<0.0001***   2.174\[1.454; 3.251\]   0.0002          19.49%, 0.2888            2.4842            0.0263                 0.9251
  NO                         5               ***2.020\[1.548; 2.636\]***   ***\<0.0001***   2.020\[1.548; 2.636\]   \<0.0001        0.00%, 0.9378             0.8047            \<0.0001               
  Tumor size                                                                                                                                                                                           
  YES                        2               ***1.714\[1.204; 2.441\]***   ***0.0028***     1.714\[1.204; 2.441\]   0.0028          0.00%, 0.8317             0.0452            \<0.0001               0.4485
  NO                         6               ***2.269\[1.742; 2.955\]***   ***\<0.0001***   2.269\[1.742; 2.955\]   \<0.0001        0.00%, 0.8851             1.7300            \<0.0001               
  Vascular invasion                                                                                                                                                                                    
  YES                        2               ***2.375\[1.481; 3.810\]***   ***0.0003***     2.375\[1.481; 3.810\]   0.0003          0.00%, 0.6755             0.1753            \<0.0001               0.7737
  NO                         6               ***1.978\[1.562; 2.507\]***   ***\<0.0001***   1.978\[1.562; 2.507\]   \<0.0001        0.00%, 0.7476             2.6905            \<0.0001               
  Tumor depth                                                                                                                                                                                          
  YES                        2               ***2.299\[1.525; 3.467\]***   ***0.0001***     2.299\[1.525; 3.467\]   0.0001          0.00%, 0.3456             0.8894            \<0.0001               0.7971
  NO                         6               ***1.970\[1.539; 2.521\]***   ***\<0.0001***   1.970\[1.539; 2.521\]   \<0.0001        0.00%, 0.8442             2.0359            \<0.0001               
  Distant metastasis                                                                                                                                                                                   
  YES                        4               ***1.965\[1.493; 2.585\]***   ***\<0.0001***   1.965\[1.493; 2.585\]   \<0.0001        0.00%, 0.5739             1.9927            \<0.0001               0.8639
  NO                         4               ***2.188\[1.569; 3.050\]***   ***\<0.0001***   2.188\[1.569; 3.050\]   \<0.0001        0.00%, 0.7786             1.0935            \<0.0001               
  Postoperative recurrence                                                                                                                                                                             
  YES                        1               ***2.160\[1.129; 4.133\]***   ***0.0200***     2.160\[1.129; 4.133\]   0.0200          NA, 1.0000                \<0.0001          NA                     0.9609
  NO                         7               ***2.040\[1.631; 2.551\]***   ***\<0.0001***   2.040\[1.631; 2.551\]   \<0.0001        0.00%, 0.7705             3.2990            \<0.0001               
  Smoking status                                                                                                                                                                                       
  YES                        1               ***2.808\[1.131; 6.969\]***   ***0.0260***     2.808\[1.131; 6.969\]   0.0260          NA, 1.0000                \<0.0001          NA                     0.7648
  NO                         7               ***2.016\[1.622; 2.506\]***   ***\<0.0001***   2.016\[1.622; 2.506\]   \<0.0001        0, 0.8283                 2.8426            \<0.0001               

HR, hazard ratio; CI, confidence interval; OS, overall survival; HCC, hepatocellular carcinoma; FEM, fixed-effect model; REM, random-effect model; NA, not available; YES, this clinicopathology parameters is the adjusted variable for OS in the included studies; NO: this clinicopathology parameters is not the adjusted variable for OS in the included studies.

I^2^, index for assessing heterogeneity; value ≥25% indicates a moderate to high heterogeneity.

Bold italics indicate statistically significant values (P \<0.05).

Correlation Between SOX2-OT Expression and Clinicopathological Characteristics {#s3_3}
------------------------------------------------------------------------------

We executed an analysis of the association between SOX2-OT expression and clinicopathological characteristics ([**Table 3**](#T3){ref-type="table"}). The results indicated that overexpression of SOX2-OT was significantly correlated with TNM stage. Higher SOX2-OT expression was associated with high TNM stage for several malignancies (n = 9, RR = 1.468; 95% CI: \[1.106--1.949\], *P* = 0.0079, I^2^ = 71.9%, [**Figure 3A**](#f3){ref-type="fig"}). SOX2-OT expression was significantly correlated with lymphatic metastasis (n = 7, RR = 1.554, 95% CI: \[1.211--1.994\], *P* = 0.0005, I^2^ = 52.2%, [**Figure 3B**](#f3){ref-type="fig"}), distant metastasis (n = 4, RR = 3.054, 95% CI: \[1.866--4.999\], *P* \< 0.0001, I^2^ = 18.3%, [**Figure 3C**](#f3){ref-type="fig"}), tumor size (n = 7, RR = 1.264, 95% CI: \[1.019--1.566\], *P* \< 0.0329, I^2^ = 56.2%, [**Figure 3D**](#f3){ref-type="fig"}), depth of tumor invasion (n = 3, RR = 1.552, 95% CI: \[1.274--1.890\], *P* \< 0.0001, I^2^ = 0.0%, [**Figure 3E**](#f3){ref-type="fig"}). However, SOX2-OT expression was not correlated with differentiation (n = 9, RR = 1.122, 95% CI: \[0.800--1.573\], *P* = 0.5062, I^2^ = 78.7%, [**Figure 3F**](#f3){ref-type="fig"}), gender (n = 8, RR = 1.022, 95% CI: \[0.921--1.134\], *P* = 0.6798, I^2^ = 0.0%, [**Figure 3G**](#f3){ref-type="fig"}), or age (n = 10, RR = 0.966, 95% CI: \[0.821--1.138\], *P* = 0.6812, I^2^ = 31.4%, [**Figure 3H**](#f3){ref-type="fig"}).

![Forest plots of main clinical parameters under the upregulation or downregulation of SOX2 overlapping transcript (SOX2-OT). **(A)** tumor, node, metastasis (TNM) stage, **(B)** lymphatic metastasis, **(C)** distant metastasis, **(D)** tumor size, **(E)** depth of tumor invasion, **(F)** differentiation, **(G)** gender, and **(H)** age.](fgene-10-01375-g003){#f3}

In order to examine the robustness of OS, the trial sequencing monitoring boundaries executed to the meta-analysis supposed a decrease in relative risk by 15%. The cumulative Z-curve crossed the trial sequential monitoring boundary for benefit, indicating that sufficient evidence exists for a 15% relative risk reduction (RRR) when SOX2-OT expression is low ([**Figure 2B**](#f2){ref-type="fig"}).

Publication bias of the association between SOX2-OT expression and prognosis was inferred based on our Egger's test (*P* \< 0.05) ([**Figure 4A**](#f4){ref-type="fig"}). No distinct biases of the correlation between SOX2-OT expression and clinicopathological characteristics were found across included studies on the basis of funnel plots and the *P* value of the Egger's test ([**Figures 4B--I**](#f4){ref-type="fig"}).

![Funnel plot for publication bias in overall survival and clinicopathological characteristics. **(A)** overall survival (OS), **(B)** tumor, node, metastasis (TNM) stage, **(C)** lymphatic metastasis, **(D)** distant metastasis, **(E)** tumor size, **(F)** depth of tumor invasion, **(G)** differentiation, **(H)** gender, and **(I)** age.](fgene-10-01375-g004){#f4}

Meta-Regression and Stratified Analysis {#s3_4}
---------------------------------------

To investigate the possible sources of heterogeneity, we gathered the original articles for subgroup analyses, based on various factors. [**Table 6**](#T6){ref-type="table"} displays the outcomes of a meta-regression that examined the source of high heterogeneity for TNM stage. The follow-up time, sample type, and tumor type could significantly explain heterogeneity for survival outcomes in the *post-hoc* analysis ([**Table 6**](#T6){ref-type="table"}, [**Figure 5A**](#f5){ref-type="fig"}). On the basis of the results of the meta-regression, we carried out a subgroup analysis on groups of patients with the follow-up time, sample type, and tumor type ([**Figures 5B--D**](#f5){ref-type="fig"}). This subgroup analysis showed a significantly lower heterogeneity in the above 60 months follow-up group, the tissue group, or the Cholangiocarcinoma group, which suggested that the relationship between high SOX2-OT expression and TNM stage has stronger efficacy in these groups.

###### 

Meta-regression analysis of heterogeneity in TNM staging.

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Moderators                         Variables of regression           HR~interaction~ (95% CI)    *P* value of regression   I^2^     Cochrane Q\
                                                                                                                                      (*P* value)
  ---------------------------------- --------------------------------- --------------------------- ------------------------- -------- -------------
  Year                               Year                              1.025(0.799--1.315)         0.8453                    75.16%   0.0002

  Sample size                        Sample size                       1.005(0.996--1.015)         0.3015                    72.91%   0.0005

  Follow up                          Follow up                         ***3.399(1.915--6.035)***   ***\<0.0001***            0.00%    0.3743

  Country                            Intercept                         1.524(1.134--2.049)         0.0052                    73.86%   0.0004

  Iran                               0.604(0.204--1.788)               0.3623                      73.86%                    0.0004   

  Sample size                        Intercept                         1.780(1.116--2.840)         0.0155                    72.38%   0.0007

  Less than 100                      0.728(0.400--1.325)               0.2993                      72.38%                    0.0007   

  Tumor type                         Intercept                         0.920(0.424--1.998)         0.8331                    0.00%    0.4329

  Cholangiocarcinoma                 ***2.621(1.071--6.412)***         ***0.0348***                0.00%                     0.4329   

  Gastric cancer                     1.881(0.806--4.390)               0.1438                      0.00%                     0.4329   

  Hepatocellular carcinoma           1.511(0.660--3.458)               0.3283                      0.00%                     0.4329   

  Osteosarcoma                       1.540(0.678--3.495)               0.3020                      0.00%                     0.4329   

  Ovarian cancer                     ***2.638(1.077--6.464)***         ***0.0338***                0.00%                     0.4329   

  Pancreatic ductal adenocarcinoma   0.601(0.239--1.513)               0.2799                      0.00%                     0.4329   

  Sample type                        Intercept                         0.553(0.297--1.029)         0.0614                    42.03%   0.0981

  Tissue                             ***2.976(1.547***--***5.725)***   ***0.0011***                42.03%                    0.0981   

  cut off value                      Intercept                         1.094(0.685--1.747)         0.7071                    69.34%   0.0033

  Median                             1.646(0.926--2.927)               0.0895                      69.34%                    0.0033   
  -------------------------------------------------------------------------------------------------------------------------------------------------

HR~interaction~, interaction effect calculated by meta-regression; Positive direction indicates that possible moderators might strengthen OS in the SOX2-OT overexpression relative to underexpression.

Bold italics indicate statistically significant values (P \< 0.05).

![Meta-regression plot and subgroup analysis of tumor, node, metastasis (TNM) stage and follow-up time, sample type and tumor type. **(A)** Meta-regression plot correction of follow-up time and TNM stage. From the meta-regression plot correction, we determined that a follow-up time of more than 60 months correlated with higher TNM stage. The point of determination for differences in TNM stage is a follow-up time of about 60 months. **(B)** Follow-up time subgroup, **(C)** sample type subtype, and **(D)** tumor type subtype.](fgene-10-01375-g005){#f5}

Meta-regression analysis ([**Supplementary Table 3**](#ST3){ref-type="supplementary-material"}) and stratified analysis ([**Supplementary Table 4**](#ST4){ref-type="supplementary-material"}) did not demonstrate heterogeneity between all potential factors and the other clinical parameters.

Validation by Independent TCGA Datasets {#s3_5}
---------------------------------------

To validate the results of the meta-analysis, we employed tissue SOX2-OT expression data and the matching survival data from TCGA datasets. The results indicated that high SOX2-OT expression in tissues was not associated with worse OS in the pooled analysis of TCGA datasets for all the tumors (n = 32, HR = 1.078, 95% CI 0.922--1.262, *P* = 0.346, I^2^ = 66.3%) ([**Table 7**](#T7){ref-type="table"}, [**Supplementary Figure 2**](#SF2){ref-type="supplementary-material"}), which included 9676 patients with diversified types of cancer.

###### 

HRs and corresponding 95% CIs of SOX2-OT overexpression in tumors based on The Cancer Genome Atlas (TCGA) datasets.

              OS                         
  ----------- -------------------------- -----------
  TCGA-LAML   1.062(0.681--1.656)        0.789
  TCGA-ACC    **0.407(0.192--0.862)**    **0.017**
  TCGA-BLCA   1.317(0.98--1.769)         0.064
  TCGA-BRCA   **1.481(1.033--2.123)**    **0.02**
  TCGA-CESC   **0.557(0.351--0.885)**    **0.014**
  TCGA-CHOL   0.918(0.364--2.319)        0.856
  TCGA-COAD   1.403(0.94--2.093)         0.109
  TCGA-ESCA   0.744(0.453--1.22)         0.248
  TCGA-HNSC   0.995(0.762--1.298)        0.97
  TCGA-KICH   0.86(0.233--3.181)         0.822
  TCGA-KIRC   **1.567(1.157--2.121)**    **0.003**
  TCGA-GBM    NA                         NA
  TCGA-KIRP   0.815(0.451--1.473)        0.5
  TCGA-LIHC   1.467(0.845--2.548)        0.24
  TCGA-LUAD   **0.738(0.552--0.988)**    **0.04**
  TCGA-LUSC   0.79(0.603--1.035)         0.085
  TCGA-DLBC   4.429(0.509--38.56)        0.059
  TCGA-MESO   **0.567(0.352--0.913)**    **0.013**
  TCGA-OV     0.921(0.711--1.193)        0.53
  TCGA-PAAD   0.89(0.591--1.339)         0.574
  TCGA-PCPG   2.648(0.526--13.329)       0.231
  TCGA-PRAD   0.541(0.155--1.883)        0.362
  TCGA-READ   1.541(0.711--3.337)        0.29
  TCGA-SARC   **1.664(1.03--2.69)**      **0.042**
  TCGA-SKCM   0.642(0.31--1.329)         0.233
  TCGA-STAD   **1.82(1.195--2.771)**     **0.022**
  TCGA-TGCT   2.269(0.314--16.419)       0.455
  TCGA-THYM   **7.349(1.494--36.153)**   **0.001**
  TCGA-THCA   **3.954(0.929--16.837)**   **0.004**
  TCGA-UCS    **2.393(1.012--5.656)**    **0.03**
  TCGA-UCEC   **2.142(1.145--4.004)**    **0.002**
  TCGA-UVM    1.461(0.645--3.311)        0.365
  TCGA-LGG    **0.662(0.465--0.941)**    **0.019**

The data were subjected to the Kaplan-Meier method and log-rank test.

HR, hazard ratio; CI, confidence interval; OS, overall survival; NA, not available.

Bold indicate statistically significant values (P \< 0.05).

ACC, adrenocortical cancer; BLCA, bladder cancer; BRCA, breast cancer; CESC, cervical cancer; CHOL, bile duct cancer; COAD, colon cancer; DLBC, diffuse Large B-cell Lymphoma; ESCA, esophageal cancer; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney Chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, glioma, LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian cancer; PAAD, pancreatic cancer; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate cancer; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, melanoma; STAD, gastric cancer; TGCT, testicular tumors; THCA, thyroid cancer; THYM, thymoma; UCEC, endometrioid cancer; UCS, uterine carcinosarcoma; UVM, uveal melanoma.

However, focusing on single tumor types combined with meta-analysis revealed that upregulation of SOX2-OT was significantly associated with worse OS in sarcoma (TCGA-SARC; HR = 1.664, 95% CI 1.03--2.69; *P* = 0.042, [**Figure 6A**](#f6){ref-type="fig"}) and gastric cancer (TCGA-STAD; HR = 1.82, 95% CI 1.195--2.771; *P* = 0.022, [**Figure 6B**](#f6){ref-type="fig"}), while the association was opposite in lung adenocarcinoma (TCGA-LUAD; HR = 0.738, 95% CI 0.552--0.988; *P* = 0.04) ([**Figure 6C**](#f6){ref-type="fig"}). In the other tumor types, SOX2-OT expression was not associated with worse OS ([**Table 7**](#T7){ref-type="table"}, [**Supplementary Figures 3**](#SF3){ref-type="supplementary-material"} **and** [**4**](#SF4){ref-type="supplementary-material"}).

![Kaplan-Meier survival curves for the overall survival of cancer patients, stratified by SOX2-OT expression levels. **(A)** TCGA-STAD, **(B)** TCGA−SARC, **(C)** TCGA−LUAD. STAD, gastric cancer; SARC, sarcoma; LUAD, lung adenocarcinoma.](fgene-10-01375-g006){#f6}

Functional Analysis of SOX2-OT Related Genes in Human Tumors {#s3_6}
------------------------------------------------------------

To systematically analyze the underlying gene regulatory mechanisms of SOX2-OT, a total of 500 target genes were identified with Multi Experiment Matrix (MEM) ([**Supplementary Figure 5**](#SF5){ref-type="supplementary-material"}). GO and KEGG analyses were executed. Validated target genes of SOX2-OT enriched GO terms including cell adhesion, cell adhesion molecule (CAM) binding, mRNA binding, mRNA splicing *via* spliceosome, and MAPK cascade ([**Figure 7A**](#f7){ref-type="fig"}). These relevant GO terms were considered as the most specific and useful for describing the concrete function of SOX2-OT. The visualization network is shown in [**Figure 7B**](#f7){ref-type="fig"}. Furthermore, KEGG enrichment analysis indicated that SOX2-OT may play a critical role in cancers *via* several pathways including CAMs, retrograde endocannabinoid signaling, circadian entrainment, cAMP signaling pathway, and mRNA surveillance pathway ([**Figure 7C**](#f7){ref-type="fig"}). These corresponding KEGG terms were considered as the most specific and useful for describing the concrete pathway of SOX2-OT. The visualization network is presented in [**Figure 7D**](#f7){ref-type="fig"}.

![Significantly enriched gene ontology (GO) categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of potential targets of long non-coding RNAs (lncRNA) SOX2 overlapping transcript (SOX2-OT) in cancer patients. **(A)** biological processes (BP), **(B)** the lncRNA SOX2-OT-GO-mRNA network was generated based on the Multi Experiment Matrix (MEM) and DAVID databases. **(C)** KEGG pathway. **(D)** the lncRNA SOX2-OT-KEGG-mRNA network was generated based on the MEM and DAVID databases.](fgene-10-01375-g007){#f7}

Discussion {#s4}
==========

Several studies have indicated that high expression of SOX2-OT is significantly related with the prognosis and clinicopathological outcomes in cancers ([@B7]; [@B16]; [@B8]; [@B27]; [@B29]; [@B23]; [@B24]; [@B6]; [@B10]; [@B11]; [@B19]; [@B25]; [@B26]). The crucial role that SOX2-OT may play in the progression of many cancers had been further outlined in reviews ([@B15]; [@B3]). A meta-analysis by Jing et al. proposed that the overexpression of SOX2-OT indicated higher TNM stage and a worse OS in cancer patients, but failed to predict distant metastasis and lymph node metastasis in Chinese cancer patients ([@B9]). Moreover, other studies since 2014 have investigated the relationship between SOX2-OT and the prognosis of cancer patients ([@B7]; [@B16]; [@B8]; [@B27]; [@B29]; [@B23]; [@B24]; [@B6]; [@B10]; [@B11]; [@B19]; [@B25]; [@B26]). The present study was performed to obtain a more definite conclusion and assess the potential mechanisms of SOX2-OT effects by integrating the outcomes of published studies and TCGA survival data and running GO and KEGG analyses.

The present meta-analysis of a combination of 1172 patients from 13 eligible studies with 9676 patients from TCGA investigated thoroughly the correlations between elevated expression of SOX2-OT and prognosis as well as clinicopathological outcomes in cancer patients. The NOS was applied to evaluate the quality of all the selected studies, and Egger's test and Begg's test were used to examine the publication bias. If the *P* value of the Egger's test was less than 0.05, we also checked the reliability of the results by TSA.

Our results indicated that elevated expression of SOX2-OT was significantly related to worse prognosis indicators, with an OS of 2.026 (95% CI: 1.691--2.428), and a DFS of 2.554 (95% CI: 1.261--5.174). Regarding the clinicopathological characteristics of patients with cancers, our research suggested that high SOX2-OT expression was significantly associated with the invasion of cancers, as reveal by the tumor stage (RR = 1.468, 95% CI: 1.106--1.949), lymphatic metastasis (RR = 1.554, 95% CI: 1.211--1.994), distant metastasis (RR = 3.054, 95% CI: 1.866--4.999), tumor size (RR = 1.264, 95% CI: 1.019--1.566), and depth of tumor invasion (RR = 1.552, 95% CI: 1.274--1.890), but couldn't predict histological differentiation, age, or gender.

According to our findings, SOX2-OT shows the potential to be used as a marker for progression and prognosis. A subgroup analysis indicated that elevated SOX2-OT expression was substantially associated with OS in sarcoma (SARC) and gastric cancer (STAD) patients, according to the publications and the TCGA datasets. As for pancreatic cancer (PAAD), bile duct cancer (CHOL), lung adenocarcinoma (LUAD), and lung squamous cell carcinoma (LUSC), SOX2-OT overexpression was correlated with a bad prognosis in the publications. However, in the TCGA datasets, SOX2-OT was associated with a good prognosis although the results were not statistically significant; the corresponding HR values were 0.89 (95% CI: 0.591--1.339, *P* = 0.574), 0.918 (95% CI: 0.364--2.319, *P* = 0.856), 0.738 (95% CI: 0.552--0.988, *P* = 0.04), and 0.79 (95% CI: 0.603--1.035, *P* = 0.085), respectively. High expression of SOX2-OT in liver cancer (LIHC) in the TCGA datasets was correlated with an unfavorable prognosis (HR = 1.467, 95% CI: 0.845--2.548, *P* = 0.24) although the results were not statistically significant, which was consistent with the publications ([@B16]; [@B19]) ([**Tables 4**](#T4){ref-type="table"} and [**7**](#T7){ref-type="table"}). Kaplan-Meier analysis initially suggested that SOX2-OT overexpression was associated with a bad OS in adrenocortical cancer (ACC), cervical cancer (CESC), mesothelioma (MESO), and glioma (LGG), and associated with a worse OS in breast cancer (BRCA), kidney renal clear cell carcinoma (KIRC), thymoma (THYM), thyroid cancer (THCA), uterine carcinosarcoma (UCS), and endometrioid cancer (UCEC) according to the TCGA datasets ([**Table 7**](#T7){ref-type="table"} and [**Supplementary Figures 3**](#SF3){ref-type="supplementary-material"} and [**4**](#SF4){ref-type="supplementary-material"}). Sampling error and publication bias may explain the inconsistent results between literature studies and studies on TCGA datasets.

Heterogeneity appeared in the clinicopathological aspects including tumor stage, lymphatic metastasis, and tumor size (*P* \< 0.1). Since the presence of heterogeneity may affect the results of the meta-analysis, the heterogeneity has been dealt cautiously with a random effects model in order to reduce the effect of heterogeneity on the merged results. Publication bias was prominent in studies with OS data (*P* \< 0.05) as showed by the Egger's, Begg's test, and funnel plots. Hence, the TSA data suggested the results of our study were statistically stable.

Recently, studies on the functioning of SOX2-OT in cancer have spread and cumulative evidence indicating that SOX2-OT could affect various biological behaviors of numerous tumors. Li et al. pointed out that SOX2-OT competitively binds to the miR-200 family to regulate the expression of SOX2, and SOX2-OT promotes epithelial-mesenchymal transition (EMT) and stem cell-like properties by regulating SOX2 expression, thereby promoting invasion and metastasis of pancreatic duct adenocarcinoma ([@B10]). Qu et al. proposed that SOX2-OT was highly expressed in gastric cancer cells, which promoted the expression of AKT2 by targeting miR-194-5p, thus elevating cell proliferation and metastasis ([@B13]). Finally, Wei et al. discovered that the upregulation of lncRNA SOX2-OT by transcription factor IRF4 promotes cell proliferation and metastasis in cholangiocarcinoma *via* upregulating SOX2, and activates PI3K/AKT signaling pathway *via* suppressing the nuclear transcription of PTEN ([@B25]).

The exact gene regulatory mechanisms of SOX2-OT remain poorly understood. Therefore, we uncovered the validated targeting genes of SOX2-OT through the MEM platform, and a comprehensive target gene network analysis was performed. The GO and KEGG pathway analysis together revealed that some CAMs and pathways may be regulated by SOX2-OT. SOX2-OT appears to play a critical role in the cancers *via* different pathways, including mRNA binding and mRNA splicing, similar to the post-transcriptional regulating functions of other lncRNAs. The above findings suggest that the elevation of SOX2-OT expression is associated with the processes of tumor invasion and metastasis, consistent with our findings.

Our study is consistent with the most recent study by Song et al. in which lncRNA SOX2-OT overexpression was significantly correlated with worse OS and more advanced clinical stages of solid tumors based on 943 cases from 10 studies, all of them being Asians ([@B17]). Consistently, analysis of 481 patients from five studies by Jing et al. showed that high SOX2-OT expression predicted poor OS and more advanced tumor progression, but failed to predict distant metastasis and lymph node metastasis in Chinese cancer patients ([@B9]). Herein, we have performed a more comprehensive study on the clinicopathological significance of SOX2-OT expression in cancer patients. First, we included 13 eligible articles involving 1172 cancer patients and 32 TCGA cancer datasets involving 9676 cancer patients to investigate a total of 10,848 participants in our study. Second, we investigated both clinicopathological and prognostic significance of SOX2-OT expression based on comprehensive clinical data and performed a series of subgroup analyses based on prognostic types, adjusted variables in the multivariate analysis of OS, sample sizes, cancer types, sample types, cut-off values, analysis models, and clinicopathological characteristics. These stratifications increase our understanding of the clinicopathological significance of SOX2-OT expression in cancers. Third, TSA on the applicable literature was used to investigate reliability and conclusiveness of available evidence for the prognostic significance of SOX2-OT expression. Fourth, the prognostic value was validated using TCGA datasets and the potential functions were explored using GO and KEGG.

In this particular study, there were some limitations. As to this meta-analysis, different cut-off values and sample types of the selected articles contributed publication bias. Since direct results of survival analysis were unavailable, a divergence in HR values might significantly contribute to extract the survival data through the Kaplan-Meier curve. Consequently, in-depth study is required to investigate the clinical value and prognosis significance of SOX2-OT in cancers.

In order to increase the sample size, we used TCGA datasets for further analysis and validation, but only the results of gastric cancer and sarcoma were consistent with those based the publications. In order to clarify the mechanism by which SOX2-OT is involved in gastric cancer and sarcoma, further molecular biology experiment is warranted to explore other possible signaling pathways or target molecules.

In conclusion, our report shows that elevated SOX2-OT expression was significantly related with invasion and metastasis progress in cancers, implying shorter OS and DFS, a poorer TNM stage, higher rates of lymphatic and distant metastasis, larger tumor size, and deeper invasion. We also concluded that SOX2-OT plays a crucial role *via* a few pathways. Considering the limitations, further studies are necessary in order to better define the functions of SOX2-OT in cancers.
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Kaplan-Meier survival curves for overall survival of 16 cancers in TCGA, stratified by SOX2-OT expression levels. **(A)** ACC, **(B)** BLCA, **(C)** BRCA, **(D)** CESC, **(E)** CHOL, **(F)** COAD, **(G)** DLBC, **(H)** ESCA, **(I)** HNSC, **(J)** KICH, **(K)** KIRC, **(L)** KIRP, **(M)** LAML, **(N)** LGG, **(O)** LIHC, **(P)** LUAD.
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Kaplan-Meier survival curves for overall survival of the other 16 cancers in TCGA, stratified by SOX2-OT expression levels. **(A)** LUSC, **(B)** MESO, **(C)** OV, **(D)** PAAD, **(E)** PCPG, **(F)** PRAD, **(G)** READ, **(H)** SARC, **(I)** SKCM, **(J)** STAD, **(K)** TGCT, **(L)** THCA, **(M)** THYM, **(N)** UCEC, **(O)** UCS, **(P)** UVM.
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Totally 500 target genes of SOX2-OT were identified with Multi Experiment Matrix (MEM).
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Databases searching terms. **(A)** Search criterion of Medline (via PubMed, from inception to Jan 1st, 2019) (n=47), **(B)** Search criterion of Embase (from 1966 to Jan 20, 2019) (n=49), **(C)** Search criterion of Cochrane Library (Jan 1st, 2019) (n=1).
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